Hypha Discovery: Experts in
MetID
Metabolite Synthesis
Purification
Structure elucidation
Natural Products

Supporting pharmaceutical and agrochemical companies globally

Your trusted partner in pharmaceutical and agrochemical R&D

What we do

Hypha Discovery is a specialist CRO supporting pharmaceutical and agrochemical companies worldwide through MetID, metabolite synthesis and identification.

We are experts in the scalable synthesis, purification and definitive identification of drug and agrochemical metabolites, and also possess a wealth of experience in the production, purification and structure elucidation of natural products.

We also use our purification expertise to isolate and identify manufacturing impurities and degradation products.

MetID services

With end-to-end expertise in metabolite identification, Hypha Discovery supports clients across the drug discovery and development process, through pinpointing metabolic soft spots in early-stage compounds to detailed MetID biotransformation studies of lead candidates and beyond. In addition to LC/MS-MS based MetID, we provide definitive structure elucidation using NMR spectroscopy.

Solutions for metabolite synthesis

We offer a comprehensive suite of techniques for provision of even the most difficult-to-synthesise metabolite, comprising chemical synthesis, recombinant enzymes such as PolyCYPs, microbial biotransformation, mammalian liver fractions as well as the purification of metabolites from biological matrices. We are also experts in the structure elucidation of metabolites by NMR spectroscopy.

Chemical Synthesis

Late-stage chemical glucuronidation

Mammalian biotransformation

Panels of liver S9s / microsomes

Microbial biotransformation

Proven panels of bacteria and fungi

Purification & structure elucidation

COAs, acquisition / interpretation of NMR data

Recombinant enzymes

PolyCYPs, PolyUGTs, hrCYPs, AOX, FMOs

Metabolite screening kits

Hypha has developed kits for scientists to make metabolites in their own labs.

PolyCYPs®+ screening kits provide a quick and convenient way to access CYP-derived and other phase I metabolites. Kits comprise 18 PolyCYP isoforms together with human aldehyde oxidase (AOX1) and the main human hepatic flavin-containing monooxygenase (FMO3). Other human FMO isoforms are available separately at Hypha. Inclusion of multiple PolyCYPs isoforms broadens coverage of reactions. They have been proven to produce human and other mammalian CYP-derived metabolites including multi-step metabolites and metabolites of low turnover drugs.

Simple, Effective, Scalable

Produce CYP, AOX & FMO metabolites

Generate multiple hydroxylated and other oxidised derivatives of lead compounds in parallel

PolyUGTs screening kits can be used to screen for, and scale-up production of, a variety of glucuronides of drugs, agrochemicals and other small molecules. The 11 enzymes in the screening kit have been tested for biocatalytic activity against a variety of drugs that undergo glucuronidation. This includes the glucuronidation of alkyl and phenolic hydroxyls to form O-glucuronides, carboxylic acids to form acyl-glucuronides, and N-glucuronidation of aromatic nitrogen-containing systems and some non-aromatic alkyl N-moieties.

Purified UGTs in an easy-to-use kit format

Produce a wide variety of glucuronides

UDPGA co-factor included

Fully scalable

About Us

Delivering a first class service to our clients worldwide

Expertise

Hypha Discovery is your trusted global partner. We are go-to experts for metabolite solutions and have worked with many of the top pharma and agrochemical companies worldwide to deliver projects.

Flexibility

We will work with you to design a custom solution that meets your needs and which can be adapted in response to project milestones.

Service

We pride ourselves on our client focused approach. Our scientists will work with you to personally deliver your project.

We contacted Hypha Discovery to generate specific phase I and phase II metabolite standards in sufficient quantities and purity to allow structural confirmation and quantitation. Hypha exceeded expectations, providing 60mg of a phase I metabolite and over 100mg of a phase II metabolite at high purity. Hypha’s team was a pleasure to work with and communicative and responsive throughout the process. We will undoubtedly be working with Hypha Discovery in the future.

Jason Boer, Associate DirectorIncyte Corporation, Wilmington, USA

The services conducted by Hypha allowed Alkermes to enhance our “Late Stage Functionalization” efforts to rapidly expand our SAR understanding inside projects. In particular, the PolarExplorer work allowed facile generation of hydroxylated compounds possessing a complex molecular core.
We look forward to engaging Hypha in the future because their team is professional, and their services complement our internal synthetic efforts for delivering new molecules.

Brian Aquila, Director of Medicinal ChemistryAlkermes, Waltham MA, USA

Hypha Discovery did a fantastic job synthesizing N- and O- glucuronides of our clinical stage drug substance. The project updates were detailed, our questions were answered in a timely manner, and the overall timeline was maintained. Hypha was highly recommended to us and I would not hesitate to recommend them to a colleague

Joshua Day Ph.D, Director of ChemistryCrestone, Inc., Colorado, USA

Hypha Discovery News

MetID Services Launch

Hypha is now offering LC-MS/MS-based MetID! We’ve expanded our capabilities to support: metabolic soft spot ID, in-depth biotransformation studies, and structural elucidation of metabolites.

Q1 2025 – Launch of PolyUGTs Kits

We’re excited that our PolyUGTs screening and scale-up kits are now available! They’re a super easy way to make glucuronides for MetID and testing in your own labs.

Welcome to Matt and Xianfu

We are delighted that Matthew Allen and Xianfu Li have joined Hypha’s team recently. Xianfu’s area of expertise is metabolite identification and bioanalysis, and Matt joins us as Hypha’s Chemistry Lab Manager.

Webinars

Tune into one of our webinars on all things metabolite related.

Blog

Check out our “Metabolite Tales” blog articles on interesting aspects around drug metabolism and medicinal chemistry.

Brochures

Access brochures on drug metabolite synthesis, Hypha’s one-stop metabolite shop, the PolyCYPs platform and PolarExplorer.

Ready to begin? Our scientists are available to talk through your requirements

Hypha Discovery is a UK-based CRO supporting pharmaceutical and agrochemical companies worldwide through the production of metabolites and new derivatives of drugs and agrochemicals in discovery and development.